How Much More Talc Fallout Will Johnson & Johnson Face After This $29 Million Verdict?
Johnson & Johnson shares dipped on Thursday on news that a California jury awarded $29 million to a woman that claimed its talcum-powder-based products caused her cancer.
A California jury has awarded $29 million to a woman who claimed talcum-powder-based Johnson & Johnson (NYSE: JNJ | JNJ Price Prediction) products caused her cancer. This ruling is the most recent defeat, out of the pool of more than 13,000 talc-related lawsuits nationwide.
Johnson & Johnson said it would appeal this verdict, citing “serious procedural and evidentiary errors” in the course of the trial. Specifically, the firm said that the lawyers for the woman fundamentally had failed to show its baby powder contains asbestos. The company did not provide further details of the alleged errors during the trial.
On its face, Johnson & Johnson denies that its talc causes cancer, saying numerous studies and tests by regulators worldwide have shown that its talc is safe and asbestos-free. For the record, the company has shown that decades of testing indicated that the use of baby powder was safe and asbestos-free.
The history of talc and asbestos cases against Johnson & Johnson is mixed. The company has won some suits that went to trial. It also faced a $4.7 billion award against it last summer in a case representing 22 women and their families. Johnson & Johnson is still appealing the verdict.
[nativounit]
An issue with environmental cases of this sort, including aspects of asbestos cases, is that there is no time limit and quantifying the ultimate financial risk is nearly impossible. Looking at the downside, it is entirely possible that the lifetime’s worth of sales of Johnson’s Baby Powder could be far lower than total damages over time if these cases end up going against the company.
Shares of Johnson & Johnson were last seen down nearly 1% at $138.15, in a 52-week range of $118.62 to $148.99. The consensus analyst target is $144.71.
[recirclink id=534508]
[wallst_email_signup]
Contact [email protected] for any questions or corrections.
Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.
His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.
When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.
